How much cash does Envoy Medical generate?

Envoy Medical (COCH) generated -$20.5M in operating cash flow over the trailing twelve months.

Where does Envoy Medical's cash flow data come from?

Every line is extracted from Envoy Medical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Envoy Medical COCH Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	-$23.11M-18.4%	-$23.76M-14.2%	-$21.79M-3.4%	-$21.27M-57.0%	-$19.52M+14.9%
Depreciation and amortization	$314K+57.0%	$302K+74.6%	$270K+56.1%	$243K+58.8%	$200K+42.9%
Stock-based compensation	$736K+22.9%	$657K+16.9%	$631K-21.4%	$603K-42.7%	$599K-54.1%
Deferred income taxes	——	-$1.89M-173%	-$770.5K-123%	$348K-91.7%	$1.47M-70.5%
Amortization of debt issuance costs	——	$1.59M—	$1.97M—	$1.77M—	——
Impairment charges	——	——	——	——	——
Change in accounts receivable	-$11K+92.5%	-$4K+87.5%	-$162K—	-$131K—	-$147K—
Change in inventories	——	——	——	——	——
Change in accounts payable	$155K-75.5%	$1.39M+7,389%	$751K—	-$87K—	$632K—
Change in accrued liabilities	——	——	——	——	——
Change in other assets	——	——	——	——	——
Change in other liabilities	——	-$868K-197%	-$428.25K—	$11.5K—	$451.25K—
Other working capital changes	——	——	——	——	$1.28M—
Change in operating lease liabilities	-$269K-74.7%	-$239K-50.3%	$1K+101%	-$937K-238%	-$154K—
Debt issuance costs and discount amortization	——	——	——	——	——
Change in receivables	-$6K+33.3%	-$761K-226%	-$13K—	-$8K—	-$9K—
Net cash from operating activities	-$20.54M-27.7%	-$18.2M-1.4%	-$17.61M+26.6%	-$15.9M+25.6%	-$16.09M+22.5%
Capital expenditures	——	$179K—	——	——	——
Acquired in-process research and development	$13.38M+26.6%	$12.49M+22.7%	$10.4M-3.3%	$10.46M+6.1%	$10.57M+12.2%
Net cash from investing activities	——	-$179K—	——	——	——
Dividends paid	——	——	——	——	——
Proceeds from issuance of debt	——	——	——	——	——
Proceeds from issuance of common stock	——	——	——	——	——
Payment of debt issuance costs	$802K-10.1%	$827K-9.7%	$849K+0.6%	$866K+8.2%	$892K+31.3%
Dividends paid on preferred stock	$5.02M-7.0%	$4.91M-11.1%	$5.17M+16.2%	$5.28M+55.1%	$5.39M+127%
Net cash from financing activities	$40.65M+135%	$16.63M-17.7%	$16.21M+11.2%	$19.53M-20.0%	$17.33M-31.1%
Effect of exchange rate changes on cash	——	——	——	——	$2K—
Net increase (decrease) in cash	——	——	-$869K—	$3.54M—	$366K—
Interest paid	$34K-15.0%	$36K-12.2%	$38K+20.6%	$38K+5.6%	$40K+19.4%
Stock-based compensation	——	——	——	——	——
Amortization Of Debt Discount Premium	——	——	——	——	——
Non-cash interest expense	——	$1.59M—	$1.97M—	$1.77M—	——
Amortization Of Prepaid Insurance	$944K-7.8%	$964K-7.9%	$976K+1.7%	$1M+19.2%	$1.02M+41.9%
Asset write-downs	——	——	——	——	——
Change In Fair Value Of Private Warrant Liability	——	——	——	——	——
Change In Fair Value Of Publicly Traded Warrant Liability	——	——	——	——	——
Change In Operating Lease Rightofuse Assetsrelated Party	$235K—	$206K—	——	——	——
Changes In Fair Value Of Warrant Liability Due To Extension	——	$24K-97.3%	$238.25K—	$452.5K—	$666.75K—
Depreciation	$314K+57.0%	$302K+74.6%	$270K+56.1%	$243K+58.8%	$200K+42.9%
Increase Decrease In Derivative Liabilities	-$222K-15.6%	-$161K+11.0%	-$228K-148%	-$220K-65.4%	-$192K—
Operating lease liabilities	-$269K-74.7%	-$239K-50.3%	$1K+101%	-$937K-238%	-$154K—
Current liabilities	——	-$868K-197%	-$428.25K—	$11.5K—	$451.25K—
Increase (Decrease) in Other Receivables	-$6K—	-$761K—	-$13K—	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	——
Charges (credits) associated with last-in, first-out inventory method	——	——	——	——	——
Satisfaction of management and incentive fees in stock	$110K—	$88K—	——	——	——
Net income	-$28.13M-5.8%	-$28.66M-2.5%	-$28.61M-7.8%	-$28.2M-58.2%	-$26.57M-3.1%
Proceeds from Collection of Long-term Loans to Related Parties	——	——	——	$62.5M—	$35M—
Dividends	——	——	——	——	$6.48M+30.2%
Offering Costs From The Issuance Of Class A Common Stock And Investor Warrants From Registered	$2.79M—	$768K—	——	——	——
Prepayment Fees on Advances, Net	——	——	——	——	——
Proceeds From Related Party Debt	——	——	——	$22.5M—	$20M—
Proceeds From Warrant Exercises	——	——	——	——	——
Sale Of Stock Consideration Received On Transaction	——	——	——	——	——
Exchange Offer (Note 12)	——	——	——	——	——
Cost of services	$961K+17.9%	$874K+17.8%	$820K+0.1%	$804K-2.1%	$815K+10.4%
Cost Of Revenue	——	——	——	——	——
Costs and Expenses	$23.36M+18.6%	$22.51M+15.5%	$20.64M-4.9%	$19.92M-1.1%	$19.69M-0.4%
Deemed Dividend On Waiver Of Restriction On Class A Common Stock	——	——	——	——	——
Effective Income Tax Rate Reconciliation Permanent Items Percent	——	——	——	——	——
Employee Benefits And Share Based Compensation	——	$37K—	——	——	——
Extinguishment Of Debt Amount	——	$32.01M—	——	——	——
General and administrative costs	$7.99M+22.1%	$7.93M+16.2%	$7.78M-7.4%	$7.02M-9.2%	$6.54M-18.1%
Other	——	$3K—	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Amount	——	$155K—	——	——	——
Induced Conversion Of Series A Preferred Stock Into Class A Common Stock	——	——	——	——	——
Interest Expense, Nonoperating	——	$1.59M+94.9%	$1.97M—	$1.77M—	$1.28M—
Litigation Settlement Expense	——	——	——	——	——
Potential civil penalty	——	——	——	——	——
Loss On Offering And Change In Fair Value Of Private Warrant Liability	-$1.63M—	$494K—	——	——	——
Net Income Loss Available To Common Stockholders Diluted	-$28.13M-5.8%	-$28.66M-2.5%	-$28.61M-7.8%	-$28.2M-58.6%	-$26.57M-3.3%
Noninterest Expense Offering Cost	——	$27.73K—	——	——	——
Other Income - Net	$13K+130%	-$1.49M+3.4%	-$1.35M—	-$1.57M—	-$43K—
Preferred Stock Dividends Per Share Cash Paid	——	——	——	——	——
Revenues	$234K+10.4%	$241K+7.1%	$208K-25.2%	$222K-26.5%	$212K-28.6%
Segment Reporting Other Item Amount	——	——	——	——	——
Sales and marketing	$1.03M-41.9%	$1.22M-29.6%	$1.64M-5.0%	$1.63M-5.9%	$1.77M+9.1%
Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions	——	$1.03M—	——	——	——
Issuance of warrants	——	——	——	$2.59M—	$1.91M—
Free cash flow	——	-$18.38M+2.9%	-$17.08M+33.1%	-$16.53M+24.0%	-$16.96M+18.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Envoy Medical.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Envoy Medical generate?: Envoy Medical (COCH) generated -$20.5M in operating cash flow over the trailing twelve months.
Where does Envoy Medical's cash flow data come from?: Every line is extracted from Envoy Medical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.